Predictive	B:C0005516
biomarkers	I:C0005516
and	O
effectiveness	O
of	O
MUC1	O
-	O
targeted	O
dendritic	O
-	I:C0011306
cell	I:C0011306
-	O
based	O
vaccine	O
in	O
patients	O
with	O
refractory	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

Predictive	O
biomarkers	I:C0005516
and	O
effectiveness	O
of	O
MUC1	B:C0006611
-	O
targeted	O
dendritic	O
-	I:C0011306
cell	I:C0011306
-	O
based	O
vaccine	O
in	O
patients	O
with	O
refractory	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

Predictive	O
biomarkers	I:C0005516
and	O
effectiveness	O
of	O
MUC1	O
-	O
targeted	O
dendritic	B:C0011306
-	I:C0011306
cell	I:C0011306
-	O
based	O
vaccine	O
in	O
patients	O
with	O
refractory	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

Predictive	O
biomarkers	I:C0005516
and	O
effectiveness	O
of	O
MUC1	O
-	O
targeted	O
dendritic	O
-	I:C0011306
cell	I:C0011306
-	O
based	O
vaccine	B:C0042210
in	O
patients	O
with	O
refractory	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

Predictive	O
biomarkers	I:C0005516
and	O
effectiveness	O
of	O
MUC1	O
-	O
targeted	O
dendritic	O
-	I:C0011306
cell	I:C0011306
-	O
based	O
vaccine	O
in	O
patients	O
with	O
refractory	B:C0677936
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

Predictive	O
biomarkers	I:C0005516
and	O
effectiveness	O
of	O
MUC1	O
-	O
targeted	O
dendritic	O
-	I:C0011306
cell	I:C0011306
-	O
based	O
vaccine	O
in	O
patients	O
with	O
refractory	O
non-small	B:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

The	O
dendritic	B:C0011306
cell	I:C0011306
(	O
dendritic	O
cell	I:C0011306
)	O
-	O
based	O
vaccine	O
targeting	O
the	O
highly	O
immunogenic	O
tumor	I:C0006611
antigen	I:C0006611
,	O
MUC1	O
,	O
has	O
been	O
promising	O
for	O
a	O
cancer	O
immunotherapy	I:C0278348
;	O
however	O
,	O
predictive	O
biomarkers	I:C0005516
for	O
beneficial	O
clinical	O
responses	I:C4055223
of	O
the	O
vaccine	O
remain	O
to	O
be	O
determined	O
.	O

The	O
dendritic	O
cell	I:C0011306
(	O
dendritic	B:C0011306
cell	I:C0011306
)	O
-	O
based	O
vaccine	O
targeting	O
the	O
highly	O
immunogenic	O
tumor	I:C0006611
antigen	I:C0006611
,	O
MUC1	O
,	O
has	O
been	O
promising	O
for	O
a	O
cancer	O
immunotherapy	I:C0278348
;	O
however	O
,	O
predictive	O
biomarkers	I:C0005516
for	O
beneficial	O
clinical	O
responses	I:C4055223
of	O
the	O
vaccine	O
remain	O
to	O
be	O
determined	O
.	O

The	O
dendritic	O
cell	I:C0011306
(	O
dendritic	O
cell	I:C0011306
)	O
-	O
based	O
vaccine	B:C0042210
targeting	O
the	O
highly	O
immunogenic	O
tumor	I:C0006611
antigen	I:C0006611
,	O
MUC1	O
,	O
has	O
been	O
promising	O
for	O
a	O
cancer	O
immunotherapy	I:C0278348
;	O
however	O
,	O
predictive	O
biomarkers	I:C0005516
for	O
beneficial	O
clinical	O
responses	I:C4055223
of	O
the	O
vaccine	O
remain	O
to	O
be	O
determined	O
.	O

The	O
dendritic	O
cell	I:C0011306
(	O
dendritic	O
cell	I:C0011306
)	O
-	O
based	O
vaccine	O
targeting	O
the	O
highly	O
immunogenic	B:C0006611
tumor	I:C0006611
antigen	I:C0006611
,	O
MUC1	O
,	O
has	O
been	O
promising	O
for	O
a	O
cancer	O
immunotherapy	I:C0278348
;	O
however	O
,	O
predictive	O
biomarkers	I:C0005516
for	O
beneficial	O
clinical	O
responses	I:C4055223
of	O
the	O
vaccine	O
remain	O
to	O
be	O
determined	O
.	O

The	O
dendritic	O
cell	I:C0011306
(	O
dendritic	O
cell	I:C0011306
)	O
-	O
based	O
vaccine	O
targeting	O
the	O
highly	O
immunogenic	O
tumor	I:C0006611
antigen	I:C0006611
,	O
MUC1	B:C0006611
,	O
has	O
been	O
promising	O
for	O
a	O
cancer	O
immunotherapy	I:C0278348
;	O
however	O
,	O
predictive	O
biomarkers	I:C0005516
for	O
beneficial	O
clinical	O
responses	I:C4055223
of	O
the	O
vaccine	O
remain	O
to	O
be	O
determined	O
.	O

The	O
dendritic	O
cell	I:C0011306
(	O
dendritic	O
cell	I:C0011306
)	O
-	O
based	O
vaccine	O
targeting	O
the	O
highly	O
immunogenic	O
tumor	I:C0006611
antigen	I:C0006611
,	O
MUC1	O
,	O
has	O
been	O
promising	O
for	O
a	O
cancer	B:C0278348
immunotherapy	I:C0278348
;	O
however	O
,	O
predictive	O
biomarkers	I:C0005516
for	O
beneficial	O
clinical	O
responses	I:C4055223
of	O
the	O
vaccine	O
remain	O
to	O
be	O
determined	O
.	O

The	O
dendritic	O
cell	I:C0011306
(	O
dendritic	O
cell	I:C0011306
)	O
-	O
based	O
vaccine	O
targeting	O
the	O
highly	O
immunogenic	O
tumor	I:C0006611
antigen	I:C0006611
,	O
MUC1	O
,	O
has	O
been	O
promising	O
for	O
a	O
cancer	O
immunotherapy	I:C0278348
;	O
however	O
,	O
predictive	B:C0005516
biomarkers	I:C0005516
for	O
beneficial	O
clinical	O
responses	I:C4055223
of	O
the	O
vaccine	O
remain	O
to	O
be	O
determined	O
.	O

The	O
dendritic	O
cell	I:C0011306
(	O
dendritic	O
cell	I:C0011306
)	O
-	O
based	O
vaccine	O
targeting	O
the	O
highly	O
immunogenic	O
tumor	I:C0006611
antigen	I:C0006611
,	O
MUC1	O
,	O
has	O
been	O
promising	O
for	O
a	O
cancer	O
immunotherapy	I:C0278348
;	O
however	O
,	O
predictive	O
biomarkers	I:C0005516
for	O
beneficial	O
clinical	B:C4055223
responses	I:C4055223
of	O
the	O
vaccine	O
remain	O
to	O
be	O
determined	O
.	O

The	O
dendritic	O
cell	I:C0011306
(	O
dendritic	O
cell	I:C0011306
)	O
-	O
based	O
vaccine	O
targeting	O
the	O
highly	O
immunogenic	O
tumor	I:C0006611
antigen	I:C0006611
,	O
MUC1	O
,	O
has	O
been	O
promising	O
for	O
a	O
cancer	O
immunotherapy	I:C0278348
;	O
however	O
,	O
predictive	O
biomarkers	I:C0005516
for	O
beneficial	O
clinical	O
responses	I:C4055223
of	O
the	O
vaccine	B:C1711297
remain	O
to	O
be	O
determined	O
.	O

DCs	B:C0011306
loaded	O
with	O
MUC1	O
-	I:C1711297
derived	I:C1711297
peptide	I:C1711297
were	O
subcutaneously	O
administered	I:C1736929
to	O
patients	O
with	O
MUC1	O
-	I:C0006611
positive	I:C0006611
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
non	O
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
that	O
was	O
refractory	O
to	O
standard	O
anticancer	O
therapies	I:C0920425
,	O
every	O
2	O
weeks	O
.	O

DCs	O
loaded	O
with	O
MUC1	B:C1711297
-	I:C1711297
derived	I:C1711297
peptide	I:C1711297
were	O
subcutaneously	O
administered	I:C1736929
to	O
patients	O
with	O
MUC1	O
-	I:C0006611
positive	I:C0006611
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
non	O
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
that	O
was	O
refractory	O
to	O
standard	O
anticancer	O
therapies	I:C0920425
,	O
every	O
2	O
weeks	O
.	O

DCs	O
loaded	O
with	O
MUC1	O
-	I:C1711297
derived	I:C1711297
peptide	I:C1711297
were	O
subcutaneously	B:C1736929
administered	I:C1736929
to	O
patients	O
with	O
MUC1	O
-	I:C0006611
positive	I:C0006611
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
non	O
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
that	O
was	O
refractory	O
to	O
standard	O
anticancer	O
therapies	I:C0920425
,	O
every	O
2	O
weeks	O
.	O

DCs	O
loaded	O
with	O
MUC1	O
-	I:C1711297
derived	I:C1711297
peptide	I:C1711297
were	O
subcutaneously	O
administered	I:C1736929
to	O
patients	O
with	O
MUC1	B:C0006611
-	I:C0006611
positive	I:C0006611
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
non	O
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
that	O
was	O
refractory	O
to	O
standard	O
anticancer	O
therapies	I:C0920425
,	O
every	O
2	O
weeks	O
.	O

DCs	O
loaded	O
with	O
MUC1	O
-	I:C1711297
derived	I:C1711297
peptide	I:C1711297
were	O
subcutaneously	O
administered	I:C1736929
to	O
patients	O
with	O
MUC1	O
-	I:C0006611
positive	I:C0006611
non-small	B:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
non	O
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
that	O
was	O
refractory	O
to	O
standard	O
anticancer	O
therapies	I:C0920425
,	O
every	O
2	O
weeks	O
.	O

DCs	O
loaded	O
with	O
MUC1	O
-	I:C1711297
derived	I:C1711297
peptide	I:C1711297
were	O
subcutaneously	O
administered	I:C1736929
to	O
patients	O
with	O
MUC1	O
-	I:C0006611
positive	I:C0006611
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
non	B:C0007131
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
that	O
was	O
refractory	O
to	O
standard	O
anticancer	O
therapies	I:C0920425
,	O
every	O
2	O
weeks	O
.	O

DCs	O
loaded	O
with	O
MUC1	O
-	I:C1711297
derived	I:C1711297
peptide	I:C1711297
were	O
subcutaneously	O
administered	I:C1736929
to	O
patients	O
with	O
MUC1	O
-	I:C0006611
positive	I:C0006611
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
non	O
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
that	O
was	O
refractory	B:C0677936
to	O
standard	O
anticancer	O
therapies	I:C0920425
,	O
every	O
2	O
weeks	O
.	O

DCs	O
loaded	O
with	O
MUC1	O
-	I:C1711297
derived	I:C1711297
peptide	I:C1711297
were	O
subcutaneously	O
administered	I:C1736929
to	O
patients	O
with	O
MUC1	O
-	I:C0006611
positive	I:C0006611
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
non	O
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
that	O
was	O
refractory	O
to	O
standard	O
anticancer	B:C0920425
therapies	I:C0920425
,	O
every	O
2	O
weeks	O
.	O

The	O
effectiveness	O
and	O
tolerability	B:C3274448
of	O
the	O
vaccine	O
were	O
evaluated	O
,	O
and	O
predictive	O
biomarkers	I:C0005516
of	O
clinical	O
responses	I:C4055223
were	O
explored	O
.	O

The	O
effectiveness	O
and	O
tolerability	O
of	O
the	O
vaccine	B:C1711297
were	O
evaluated	O
,	O
and	O
predictive	O
biomarkers	I:C0005516
of	O
clinical	O
responses	I:C4055223
were	O
explored	O
.	O

The	O
effectiveness	O
and	O
tolerability	O
of	O
the	O
vaccine	O
were	O
evaluated	O
,	O
and	O
predictive	B:C0005516
biomarkers	I:C0005516
of	O
clinical	O
responses	I:C4055223
were	O
explored	O
.	O

The	O
effectiveness	O
and	O
tolerability	O
of	O
the	O
vaccine	O
were	O
evaluated	O
,	O
and	O
predictive	O
biomarkers	I:C0005516
of	O
clinical	B:C4055223
responses	I:C4055223
were	O
explored	O
.	O

Between	O
August	O
2005	O
and	O
May	O
2015	O
,	O
40	O
patients	O
received	O
the	O
vaccines	B:C1711297
.	O

The	O
median	O
survival	O
time	O
(	O
MST	O
)	O
after	O
the	O
initial	O
vaccination	B:C0042196
was	O
7.4	O
months	O
,	O
and	O
the	O
1	O
-	O
year	O
survival	O
rate	O
was	O
25.0	O
%	O
.	O

The	O
MST	O
for	O
patients	O
who	O
received	O
more	O
than	O
six	O
vaccinations	B:C0042196
was	O
9.5	O
months	O
,	O
and	O
the	O
1	O
-	O
year	O
survival	O
rate	O
was	O
39.3	O
%	O
.	O

In	O
this	O
cohort	B:C0599755
,	O
patients	O
who	O
experienced	O
immune	O
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
,	O
including	O
skin	O
reactions	I:C1142480
at	I:C1142480
the	I:C1142480
vaccination	I:C1142480
site	I:C1142480
and	O
fever	O
,	O
had	O
significantly	O
longer	O
survival	I:C2919552
times	I:C2919552
compared	O
with	O
patients	O
without	O
those	O
immune	O
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
(	O
12.6	O
versus	O
6.7	O
months	O
,	O
p	O
=	O
0.042	O
)	O
.	O

In	O
this	O
cohort	O
,	O
patients	O
who	O
experienced	O
immune	B:C0877248
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
,	O
including	O
skin	O
reactions	I:C1142480
at	I:C1142480
the	I:C1142480
vaccination	I:C1142480
site	I:C1142480
and	O
fever	O
,	O
had	O
significantly	O
longer	O
survival	I:C2919552
times	I:C2919552
compared	O
with	O
patients	O
without	O
those	O
immune	O
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
(	O
12.6	O
versus	O
6.7	O
months	O
,	O
p	O
=	O
0.042	O
)	O
.	O

In	O
this	O
cohort	O
,	O
patients	O
who	O
experienced	O
immune	O
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
,	O
including	O
skin	B:C1142480
reactions	I:C1142480
at	I:C1142480
the	I:C1142480
vaccination	I:C1142480
site	I:C1142480
and	O
fever	O
,	O
had	O
significantly	O
longer	O
survival	I:C2919552
times	I:C2919552
compared	O
with	O
patients	O
without	O
those	O
immune	O
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
(	O
12.6	O
versus	O
6.7	O
months	O
,	O
p	O
=	O
0.042	O
)	O
.	O

In	O
this	O
cohort	O
,	O
patients	O
who	O
experienced	O
immune	O
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
,	O
including	O
skin	O
reactions	I:C1142480
at	I:C1142480
the	I:C1142480
vaccination	I:C1142480
site	I:C1142480
and	O
fever	B:C2349672
,	O
had	O
significantly	O
longer	O
survival	I:C2919552
times	I:C2919552
compared	O
with	O
patients	O
without	O
those	O
immune	O
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
(	O
12.6	O
versus	O
6.7	O
months	O
,	O
p	O
=	O
0.042	O
)	O
.	O

In	O
this	O
cohort	O
,	O
patients	O
who	O
experienced	O
immune	O
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
,	O
including	O
skin	O
reactions	I:C1142480
at	I:C1142480
the	I:C1142480
vaccination	I:C1142480
site	I:C1142480
and	O
fever	O
,	O
had	O
significantly	O
longer	B:C2919552
survival	I:C2919552
times	I:C2919552
compared	O
with	O
patients	O
without	O
those	O
immune	O
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
(	O
12.6	O
versus	O
6.7	O
months	O
,	O
p	O
=	O
0.042	O
)	O
.	O

In	O
this	O
cohort	O
,	O
patients	O
who	O
experienced	O
immune	O
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
,	O
including	O
skin	O
reactions	I:C1142480
at	I:C1142480
the	I:C1142480
vaccination	I:C1142480
site	I:C1142480
and	O
fever	O
,	O
had	O
significantly	O
longer	O
survival	I:C2919552
times	I:C2919552
compared	O
with	O
patients	O
without	O
those	O
immune	B:C0877248
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
(	O
12.6	O
versus	O
6.7	O
months	O
,	O
p	O
=	O
0.042	O
)	O
.	O

Longer	B:C2919552
survival	I:C2919552
times	I:C2919552
were	O
also	O
observed	O
in	O
patients	O
whose	O
peripheral	O
white	I:C0023508
blood	I:C0023508
cells	I:C0023508
contained	O
>	O
20.0	O
%	O
lymphocytes	O
(	O
12.6	O
versus	O
4.5	O
months	O
;	O
p	O
=	O
0.014	O
)	O
.	O

Longer	O
survival	I:C2919552
times	I:C2919552
were	O
also	O
observed	O
in	O
patients	O
whose	O
peripheral	B:C0023508
white	I:C0023508
blood	I:C0023508
cells	I:C0023508
contained	O
>	O
20.0	O
%	O
lymphocytes	O
(	O
12.6	O
versus	O
4.5	O
months	O
;	O
p	O
=	O
0.014	O
)	O
.	O

Longer	O
survival	I:C2919552
times	I:C2919552
were	O
also	O
observed	O
in	O
patients	O
whose	O
peripheral	O
white	I:C0023508
blood	I:C0023508
cells	I:C0023508
contained	O
>	O
20.0	O
%	O
lymphocytes	B:C0200635
(	O
12.6	O
versus	O
4.5	O
months	O
;	O
p	O
=	O
0.014	O
)	O
.	O

MUC1	B:C1711297
-	O
specific	O
cytotoxic	O
immune	I:C1817908
responses	I:C1817908
were	O
achieved	O
in	O
all	O
of	O
seven	O
patients	O
analyzed	O
who	O
received	O
six	O
vaccinations	O
.	O

MUC1	O
-	O
specific	O
cytotoxic	B:C1817908
immune	I:C1817908
responses	I:C1817908
were	O
achieved	O
in	O
all	O
of	O
seven	O
patients	O
analyzed	O
who	O
received	O
six	O
vaccinations	O
.	O

MUC1	O
-	O
specific	O
cytotoxic	O
immune	I:C1817908
responses	I:C1817908
were	O
achieved	O
in	O
all	O
of	O
seven	O
patients	O
analyzed	O
who	O
received	O
six	O
vaccinations	B:C0042196
.	O

The	O
MUC1	B:C1711297
-	O
targeted	O
dendritic	O
cell	I:C0011306
-	O
based	O
vaccine	O
induced	O
an	O
antitumor	O
immune	O
response	I:C0301872
that	O
promoted	O
prolonged	O
survival	I:C2919552
of	O
patients	O
with	O
refractory	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

The	O
MUC1	O
-	O
targeted	O
dendritic	B:C0011306
cell	I:C0011306
-	O
based	O
vaccine	O
induced	O
an	O
antitumor	O
immune	O
response	I:C0301872
that	O
promoted	O
prolonged	O
survival	I:C2919552
of	O
patients	O
with	O
refractory	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

The	O
MUC1	O
-	O
targeted	O
dendritic	O
cell	I:C0011306
-	O
based	O
vaccine	B:C1711297
induced	O
an	O
antitumor	O
immune	O
response	I:C0301872
that	O
promoted	O
prolonged	O
survival	I:C2919552
of	O
patients	O
with	O
refractory	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

The	O
MUC1	O
-	O
targeted	O
dendritic	O
cell	I:C0011306
-	O
based	O
vaccine	O
induced	O
an	O
antitumor	O
immune	B:C0301872
response	I:C0301872
that	O
promoted	O
prolonged	O
survival	I:C2919552
of	O
patients	O
with	O
refractory	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

The	O
MUC1	O
-	O
targeted	O
dendritic	O
cell	I:C0011306
-	O
based	O
vaccine	O
induced	O
an	O
antitumor	O
immune	O
response	I:C0301872
that	O
promoted	O
prolonged	B:C2919552
survival	I:C2919552
of	O
patients	O
with	O
refractory	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

The	O
MUC1	O
-	O
targeted	O
dendritic	O
cell	I:C0011306
-	O
based	O
vaccine	O
induced	O
an	O
antitumor	O
immune	O
response	I:C0301872
that	O
promoted	O
prolonged	O
survival	I:C2919552
of	O
patients	O
with	O
refractory	B:C0677936
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

The	O
MUC1	O
-	O
targeted	O
dendritic	O
cell	I:C0011306
-	O
based	O
vaccine	O
induced	O
an	O
antitumor	O
immune	O
response	I:C0301872
that	O
promoted	O
prolonged	O
survival	I:C2919552
of	O
patients	O
with	O
refractory	O
non-small	B:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

The	O
occurrence	O
of	O
immune	B:C0877248
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
and	O
having	O
a	O
higher	O
percentage	O
of	O
peripheral	O
lymphocytes	I:C0200635
were	O
predictive	O
biomarkers	I:C0005516
of	O
a	O
beneficial	O
clinical	O
response	I:C4055223
during	O
cancer	O
immunotherapy	I:C0278348
for	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

The	O
occurrence	O
of	O
immune	O
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
and	O
having	O
a	O
higher	O
percentage	O
of	O
peripheral	B:C0200635
lymphocytes	I:C0200635
were	O
predictive	O
biomarkers	I:C0005516
of	O
a	O
beneficial	O
clinical	O
response	I:C4055223
during	O
cancer	O
immunotherapy	I:C0278348
for	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

The	O
occurrence	O
of	O
immune	O
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
and	O
having	O
a	O
higher	O
percentage	O
of	O
peripheral	O
lymphocytes	I:C0200635
were	O
predictive	B:C0005516
biomarkers	I:C0005516
of	O
a	O
beneficial	O
clinical	O
response	I:C4055223
during	O
cancer	O
immunotherapy	I:C0278348
for	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

The	O
occurrence	O
of	O
immune	O
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
and	O
having	O
a	O
higher	O
percentage	O
of	O
peripheral	O
lymphocytes	I:C0200635
were	O
predictive	O
biomarkers	I:C0005516
of	O
a	O
beneficial	O
clinical	B:C4055223
response	I:C4055223
during	O
cancer	O
immunotherapy	I:C0278348
for	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

The	O
occurrence	O
of	O
immune	O
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
and	O
having	O
a	O
higher	O
percentage	O
of	O
peripheral	O
lymphocytes	I:C0200635
were	O
predictive	O
biomarkers	I:C0005516
of	O
a	O
beneficial	O
clinical	O
response	I:C4055223
during	O
cancer	B:C0278348
immunotherapy	I:C0278348
for	O
non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

The	O
occurrence	O
of	O
immune	O
-	I:C0877248
related	I:C0877248
adverse	I:C0877248
events	I:C0877248
and	O
having	O
a	O
higher	O
percentage	O
of	O
peripheral	O
lymphocytes	I:C0200635
were	O
predictive	O
biomarkers	I:C0005516
of	O
a	O
beneficial	O
clinical	O
response	I:C4055223
during	O
cancer	O
immunotherapy	I:C0278348
for	O
non-small	B:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
.	O

